| • High degree of clinical suspicion for the diagnosis of tuberculosis due to the similarity of symptoms with those of COVID-19. |
| • In settings with a high tuberculosis burden, the possibility of a concomitant diagnosis of tuberculosis and COVID-19 should always be considered. |
| • Development of algorithms for the management of the tuberculosis/COVID-19 combination can improve outcomes. |
| • The doses of antituberculosis drugs with hepatotoxic or nephrotoxic potential should be adjusted in patients with severe COVID-19 who show changes in liver and kidney function. |
| • Remember that the prolonged use of corticosteroids for the treatment of post-COVID-19 organizing pneumonia may result in tuberculosis reactivation. |
| • Remember that COVID-19 can lead to sequelae, such as pulmonary fibrosis, which can reduce the penetration of antituberculosis drugs in the lungs, contributing to poor outcomes, as well as to the development of multidrug-resistant tuberculosis. |
| • Patients with tuberculosis and COVID-19 may be at a greater risk of poor outcomes and death than are those with COVID-19 alone. Therefore, early detection of the combination is important for the proper management of both diseases. |
| • Adequate isolation of tuberculosis patients, thus minimizing their exposure to SARS-CoV-2, can prevent coinfection. |
| • Remember that patients with pulmonary sequelae due to COVID-19 may have a higher risk of developing tuberculosis in the future. |
| • The diagnosis and management of latent tuberculosis infection can be affected by the immune dysregulation caused by COVID-19. |
